Skip to main content

Milestone 5.B

Initiate phase II (proof of concept) drug trials for agents against 3-6 currently known therapeutic targets. Of these at least 2 will be for targets involved in at-risk asymptomatic individuals (e.g. FAD or ApoE4 carriers, Down syndrome, amyloid positive, type II diabetes, etc.)  These trials will be designed to provide or confirm proof of mechanism and/or evidence of target engagement for the therapeutic agent being tested. 


Success Criteria

  • Completion of 3-6 phase II drug trials for agents against currently known targets, providing conclusive evidence of therapeutic mechanism/target engagement.


Research Implementation Area
Drug Development - Existing Targets
Timeline
2015–2023
Status
In Progress

Implementation Activities

Funding Initiatives

Research Programs and Resources

Research Highlights

Relevant Recommendations